EHA 2021 | Final analysis of UVEA-IXA study of ixazomib in R/R myeloma
Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, reports on the final results of the UVEA-IXA study, investigating ixazomib-based therapy in patients with relapsed or refractory (R/R) myeloma, outside of a clinical trial. The study reviewed data from patients in biochemical or symptomatic relapse after 1-3 prior lines of therapy who were subsequently treated with ixazomib. The final analysis of results from this study indicate that ixazomib is an effective and tolerable therapy outside of clinical trials. Prof. Ludwig compares the data collected in this study with data from the TOURMALINE-MM1 trial (NCT01564537). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Prof. Heinz Ludwig, MD, has received research funding from Amgen and Takeda; has been a member of a speakers bureau with Celgene, Janssen, Bristol Myers, Sanofi and Amgen; and has participated in advisory boards for Janssen, Bristol Myers, Sanofi, Amgen and Seattle Genetics.
